Follows survival and treatment sequences in people with chronic lymphocytic leukemia
Observes long-term survival in adults with chronic lymphocytic leukemia after first-line treatment.
Plain-language title generated from the registry record
Registry title: A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG
Key facts
- Where
- Cologne and Ulm, GermanySee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic lymphocytic leukaemia (CLL) who had first-line treatment in a GCLLSG study (CLL13, CLL14 or CLL17). It follows how long they live.
- Age
- 18 to 99 years
- Sex
- All sexes
- Disease stage
- Documented CLL when joining a first-line GCLLSG study. Developing Richter transformation (RT) does not stop a person from joining.
- Earlier treatment
- First-line treatment given within the GCLLSG study CLL13, CLL14 or CLL17. Later treatments were recorded in that study, or the person agrees to have them recorded here.
Main reasons for not taking part
- Did not take part in the GCLLSG first-line study CLL13, CLL14 or CLL17
- Legally unable to give consent
- Placed in an institution by an official or court order
- Dependent on the sponsor or the investigator
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06792994, who can take part
Where in Germany
- University Hospital CologneCologne, GermanyContact: NAdine Kutsch, MDTaking people
- Universitätsklinikum UlmUlm, GermanyContact: Kirsten Fischer, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- German CLL Study Group
- Trial code
- NCT06792994
- Record updated
- 30 April 2026
- Original description
This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.Read full original descriptionShow less
A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG
This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.
Inclusion: • Subjects must voluntarily sign and date an informed consent, ap-proved by an independent ethics committee (IEC)/institutional review board (IRB); Documented diagnosis of CLL at time point of inclusion in a first-line study of the GCLLSG (development of RT is not an exclusion criterion); First-line treatment was administered within one of these first-line studies of the GCLLSG (CLL13, CLL14, or CLL17); Subsequent therapy lines were either documented during the participa-tion in a first-line study of the GCLLSG or patient consented to have the subsequent therapy lines documented within this observational trial; Subjects are willing and able to comply with procedures required in this protocol.
Exclusion: • Patients without participation in one of the first-line studies of the GCLLSG (CLL13, CLL14, CLL17); Subjects with legal incapacity; Subjects who are institutionalized by regulatory or court order; Subjects who are in dependence to the sponsor or the investigator.